A practical reference on freeze-thaw cycle: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-18. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
==== Current usage in medicine ==== Desmosine is currently used as a biomarker in the medical field. It is measured in order to monitor elastin breakdown. Since it is connected to the degradation of elastin, it can be used to identify COPD. Desmosine is one of the oldest biomarkers and was developed in the 1960s, but the first time it was correlated to lung elastin content was in the 80s through urinary excretion. Biomarkers are judged in 6 ways:
Marvel Comics editor-in-chief Roy Thomas wanted to create a Canadian superhero and decided that wolverines were a typical Canadian animal that could inspire such a hero. He asked artist John Romita Sr. and writer Len Wein to devise a character of Canadian origin named Wolverine. Romita designed Wolverine's costume. Wolverine first appeared in the final "teaser" panel of The Incredible Hulk #180 (cover-dated October 1974), written by Wein and penciled by Herb Trimpe. The character then appeared in a number of advertisements in various Marvel Comics publications before making his first major appearance in The Incredible Hulk #181 (November 1974), again by the Wein–Trimpe team. In 2009, Trimpe said he "distinctly remembers" Romita's sketch and that, according to him, Romita and Wein "sewed the monster together [while he] shocked it to life". According to him, Wolverine was initially conceived as a minor character and there were no plans for his continuing popularity. Though sometimes credited as co-creator, Trimpe denied having had any role in Wolverine's creation. The character's introduction was ambiguous, revealing little beyond his being a superhuman agent of the Canadian government. He appears briefly in the following issue's conclusion to the story. Wolverine's next appearance was in Giant-Size X-Men (May 1975), written by Wein and penciled by Dave Cockrum, in which he is recruited for a new team of X-Men to rescue the original group. Gil Kane illustrated the cover artwork but drew Wolverine's mask with larger headpieces.
As he expected, withdrawal of the drug led to an increase in seizure frequency – it was not a cure. The drug was quickly adopted as the first widely effective anticonvulsant, though World War I delayed its introduction in the U.S. In 1939, a German family asked Adolf Hitler to have their disabled son killed; the five-month-old boy was given a lethal dose of Luminal after Hitler sent his own doctor to examine him. A few days later 15 psychiatrists were summoned to Hitler's Chancellery and directed to commence a clandestine program of involuntary euthanasia. In 1940, at a clinic in Ansbach, Germany, around 50 intellectually disabled children were injected with Luminal and killed that way. A plaque was erected in their memory in 1988 in the local hospital at Feuchtwanger Strasse 38, although a newer plaque does not mention that patients were killed using barbiturates on site. Luminal was used in the Nazi children's euthanasia program until at least 1943. Phenobarbital was used to treat neonatal jaundice by increasing liver metabolism and thus lowering bilirubin levels. In the 1950s, phototherapy was discovered, and became the standard treatment. Phenobarbital was used for over 25 years as prophylaxis in the treatment of febrile seizures. Although an effective treatment in preventing recurrent febrile seizures, it had no positive effect on patient outcome or risk of developing epilepsy. The treatment of simple febrile seizures with anticonvulsant prophylaxis is no longer recommended.
== Further reading == Jung, Hans Joachim (2000). Panzer Soldiers for "God, Honor and Fatherland": The History of Panzerregiment Grossdeutschland. Winnipeg, Canada: J. J. Fedorowicz. ISBN 0-921991-51-7. Herbst, Jurgen (2002). Requiem for a German Past: A Boyhood among the Nazis. Madison, Wisconsin: University of Wisconsin Press. ISBN 978-0-299-16414-0. de Lannoy, François; Perrigault, Jean-Claude (1998). La Grossdeutschland: du régiment au Panzerkorps, 1939–1945 [Grossdeutschland: From Regiment to Panzer Corps 1939–1945] (in French). Bayeux, France: Heimdal. ISBN 2-84048-110-3. Lucas, James (1978). Germany's Elite Panzer Force: Grossdeutschland. London: Macdonald and Jane's. ISBN 0-35401-165-0. McGuirl, Thomas; Spezzano, Remy (1997). God, Honor, Fatherland: A Photo History of Panzergrenadier Division Grossdeutschland on the Eastern Front 1942 - 1944. Connecticut: Southbury. ISBN 0-9657584-0-0. Novotny, Alfred (2002). The Good Soldier: From Austrian Social Democracy to Communist Captivity with a Soldier of Panzer-Grenadier Division Grossdeutschland. Bedford, Pennsylvania: Aberjona Press. ISBN 0-966638-99-9. Quarrie, Bruce (1977). Panzer-Grenadier Division Grossdeutschland. London: Osprey Publishing Group. ISBN 0-85045-055-1.
Sources: en.wikipedia.org
φ29’s DNA packaging system, using pRNA, incorporates a motor for the delivery of therapeutic molecules like ribozymes and aptamers. The small size of pRNA-derived nanoparticles also helps to deliver drugs in tight spaces like blood vessels. The main difficulty in using aptamer-based drug delivery is sourcing unique aptamers and other multimers for specific treatments for diseases that potentially degrade therapeutic multimers and nanoparticles in vivo. Nanoparticles need to be stabilized as delivery mechanisms in order to adapt to microenvironments that may result in loss of therapeutic cargo.
== Astrophysical dating == Knowledge of current and theoretical production ratios of uranium-235 to uranium-238 allows radiometric dating, the time since modern uranium nuclei were formed in stellar nucleosynthesis. The 1957 B2FH landmark paper in astrophysics explained the r-process by which both nuclei form. The authors predicted their relative abundances, and those of their rapidly alpha-chain decaying parent nuclides. Thus they predicted 1.64 as the 235U/238U ratio contributed to the interstellar medium by r-process events (supernovae and subsequently discovered kilonovae). This takes billions of years to diminish to their present value of 0.0072 (see natural uranium). They investigate scenarios for historical contribution to the solar nebula, before contribution is cut off at the Sun's formation 4.5 billion years ago. The scenarios are: a single supernova, a finite continuous uniform series of supernovae representing the lifetime of the Milky Way, and an infinite series representing the steady-state universe. From the second scenario, they estimated an age of the Milky Way at around 10 billion years, compared to a modern value of 13.61 billion years. At the time, the oldest known objects were globular clusters, of which the oldest were estimated to be about 6.5 billion years old.
Émile Zuckerkandl (July 4, 1922 – November 9, 2013) was an Austrian-born French biologist considered one of the founders of the field of molecular evolution. He introduced, with Linus Pauling, the concept of the "molecular clock", which enabled the neutral theory of molecular evolution.
On November 19, 2019, a lawsuit was filed by a vegan from Atlanta, Georgia, against Burger King for allegedly failing to clearly disclose that Impossible Whopper burgers were heated on the same grill as their beef burgers. The lawsuit was dismissed. On March 28, 2022, a lawsuit was filed against Burger King, alleging the fast food chain falsely advertised the Whopper to "look about 35% bigger in its advertising than it is in reality". On May 5, 2025, Federal Judge Roy Altman allowed the case to proceed, stating the claims may reasonably suggest consumers were misled and that Florida law permits such misrepresentation suits without a special relationship. Burger King argued that differences between ads and actual burgers are typical of handmade food and standard marketing practices.
=== Exercise === In 2017, exercise was the only fibromyalgia treatment given a strong recommendation by the European Alliance of Associations for Rheumatology (EULAR). There is strong evidence indicating that exercise improves fitness, sleep and quality of life and may reduce pain and fatigue for people with fibromyalgia. The rate of adverse events reported in studies of exercise is low, with the most common being muscle pain, and no serious adverse events reported. There are several hypothesized biological mechanisms for exercise benefits in FM. Exercise may improve pain modulation through serotonergic pathways. It may reduce pain by altering the hypothalamic-pituitary-adrenal axis and reducing cortisol levels. It also has anti-inflammatory effects that may improve fibromyalgia symptoms. Aerobic exercise can improve muscle metabolism and pain through mitochondrial pathways. Despite its benefits, exercise is a challenge for patients with fibromyalgia, due to the chronic fatigue and pain they experience. They may have negative experiences with being given non-personalized exercise programs by healthcare providers who they feel do not understand the impact of the condition. Adherence is higher when the exercise program is recommended by doctors or supervised by nurses. Sufferers perceive exercise as more effortful than healthy adults. Depression and higher pain intensity serve as barriers to physical activity. A recommended approach to a graded exercise program begins with small, frequent exercise periods and builds up from there.
Sources: en.wikipedia.org
However, the dependence on some of these properties is negligible in certain cases. For example, the viscosity of a Newtonian fluid does not vary significantly with the rate of deformation. Zero viscosity (no resistance to shear stress) is observed only at very low temperatures in superfluids; otherwise, the second law of thermodynamics requires all fluids to have positive viscosity. A fluid that has zero viscosity (non-viscous) is called ideal or inviscid. For non-Newtonian fluids' viscosity, there are pseudoplastic, plastic, and dilatant flows that are time-independent, and there are thixotropic and rheopectic flows that are time-dependent.
Protein digestibility-corrected amino acid score (PDCAAS) is a method of evaluating the quality of a protein based on both the amino acid requirements of humans and their ability to digest it. The PDCAAS rating was recommended by the Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO) in 1989 (report published in 1991). It was adopted by the US FDA in 1993 as "the preferred 'best'" method to determine protein quality. In 2013, FAO proposed changing to Digestible Indispensable Amino Acid Score.
== Track listing == "The Death of a Dream" - 0:48 "Control Alt Delete" - 2:15 "Do You Have a Map, Because I'm Lost in Your Eyes" - 3:08 "The Girl That Destroyed Me" - 2:34 "Candycanes and Cola" - 3:06 "Audrey in Sacramento" - 2:41 "Photograph" - 2:27 "Until Her Heart Stops" - 2:56 "I'm Not Crying, My Eyeballs Are Sweating" - 2:35
=== Development === In at least one knock-out study of the gene, mice without thymosin β4 still had apparently normal embryonic development, and were fertile as adults (in contrast to an earlier knock-out study). This calls into some question the developmental importance of the protein.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Low temperature slows the chemical reactions, such as oxidation and hydrolysis, that break down a peptide chain. Water and oxygen are the main drivers of degradation, so a cold and dry environment extends usable life. Actual shelf life depends on the batch, the salt form, and the container.